CG Oncology, Inc. (CGON) Institutional Ownership

Ownership Summary

CG Oncology, Inc. (NASDAQ:CGON) appears in 190 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 102.9% of CG Oncology's outstanding shares in December 2025, up from 102.5% in September 2025.
• They increased total shares held in CGON by 6.34% quarter over quarter, and investors in CG Oncology increased 36.69% from a year ago.
• Of these 190 holders, 110 added to their stakes in CG Oncology, 53 trimmed positions, and 27 made no changes.
• The aggregate institutional position in CG Oncology amounted to 78.95Mn shares as of December 2025, up by 4.71Mn shares quarter on quarter, and up 9.66Mn shares year over year.
• RTW INVESTMENTS, LP is the top holder of CG Oncology as of December 31, 2025, with 6.98Mn shares representing 9.1% of outstanding stock.
• The biggest buyers of CG Oncology for the quarter ending December 2025 included T. Rowe Price Investment Management, Inc. (6.26Mn), RTW INVESTMENTS, LP (4.97Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.65Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (3.1Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.03Mn).
• The largest sellers of CG Oncology for the quarter ending December 2025 were Seven Fleet Capital Management LP (2.95Mn), Goldman Sachs Group Inc (1.49Mn), Pictet Asset Management Holding SA (951.52K), BRAIDWELL LP (885.79K), Opaleye Management Inc. (725.2K).
• CG Oncology's 10 largest shareholders as of December 2025 include RTW INVESTMENTS, LP (6.98Mn), T. Rowe Price Investment Management, Inc. (6.72Mn), Decheng Capital LLC (6.37Mn), WELLINGTON MANAGEMENT GROUP LLP (5.37Mn), BlackRock, Inc. (5.06Mn), FMR LLC (3.76Mn), TCG Crossover Management, LLC (3.67Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.65Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (3.1Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.03Mn) per Business Quant data.